

DAFTAR PUSTAKA

- Abbasi-Ghahramanloo, A., Soltani-Kermanshahi, M., Mansori, K., Khazaei-Pool, M., Sohrabi, M., Baradaran, H.R., Talebloo, Z. and Gholami, A., 2020. Comparison of SF-36 and WHOQoL-BREF in Measuring Quality of Life in Patients with Type 2 Diabetes. *International Journal of General Medicine*, Volume 13, pp.497–506. <https://doi.org/10.2147/IJGM.S258953>.
- Aksaraliksunti, M. and Sanmaneechai, O., 2022a. Health-related quality of life in Thai children with spinal muscular atrophy. *Pediatrics & Neonatology*, 63(3), pp.291–297. <https://doi.org/10.1016/j.pedneo.2022.01.002>.
- Aksaraliksunti, M. and Sanmaneechai, O., 2022b. Health-related quality of life in Thai children with spinal muscular atrophy. *Pediatrics & Neonatology*, 63(3), pp.291–297. <https://doi.org/10.1016/j.pedneo.2022.01.002>.
- Ansah, J.P. and Chiu, C.-T., 2023. Projecting the chronic disease burden among the adult population in the United States using a multi-state population model. *Frontiers in Public Health*, 10. <https://doi.org/10.3389/fpubh.2022.1082183>.
- Arnold, W.D., Kassar, D. and Kissel, J.T., 2015. Spinal muscular atrophy: Diagnosis and management in a new therapeutic era. *Muscle & Nerve*, 51(2), pp.157–167. <https://doi.org/10.1002/mus.24497>.
- Bertini, E., Dessaud, E., Mercuri, E., Muntoni, F., Kirschner, J., Reid, C., Lusakowska, A., Comi, G.P., Cuisset, J.-M., Abitbol, J.-L., Scherrer, B., Ducray, P.S., Buchbjerg, J., Vianna, E., van der Pol, W.L., Vuillerot, C., Blaettler, T., Fontoura, P., André, C., Bruno, C., Chabrol, B., Deconinck, N., Estournet, B., Fontaine-Carbonnel, S., Goemans, N., Gorni, K., Govoni, A., Guglieri, M., Lochmuller, H., Magri, F., Mayer, M., Müller-Felber, W., Rivier, F., Roper, H., Schara, U., Scoto, M., van den Berg, L., Vita, G. and Walter, M.C., 2017. Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial. *The Lancet Neurology*, 16(7), pp.513–522. [https://doi.org/10.1016/S1474-4422\(17\)30085-6](https://doi.org/10.1016/S1474-4422(17)30085-6).
- Błauciak, M., Ubysz, J., Pokryszko-Dragan, A. and Koszewicz, M., 2024. The Impact of Comorbidities and Motor Impairment on the Quality of Life of Patients with Spinal Muscular Atrophy: A Case–Control Study. *Journal of Clinical Medicine*, 13(14), p.4184. <https://doi.org/10.3390/jcm13144184>.
- Britton, D., Hoit, J.D., Pullen, E., Benditt, J.O., Baylor, C.R. and Yorkston, K.M., 2019. Experiences of Speaking With Noninvasive Positive Pressure Ventilation: A Qualitative Investigation. *American Journal of Speech-*

Language Pathology, 28(2S), pp.784–792.
https://doi.org/10.1044/2019_AJSLP-MSCL18-18-0101.

Budler, L.C., Pajnikihar, M., Ravens-Sieberger, U., Barr, O. and Stiglic, G., 2022. The KIDSCREEN-27 scale: translation and validation study of the Slovenian version. *Health and Quality of Life Outcomes*, 20(1), p.67.
<https://doi.org/10.1186/s12955-022-01973-3>.

Callan, A., Nallagangula, T.K., Jawla, S. and Risson, V., 2018. PSY27 - SPINAL MUSCULAR ATROPHY: A REVIEW OF EPIDEMIOLOGY, BURDEN AND UNMET NEEDS. *Value in Health*, 21, p.S440.
<https://doi.org/10.1016/j.jval.2018.09.2604>.

Chan, S.H.S., Wong, C.K.H., Wu, T., Wong, W., Yu, M.K.L., Au, I.C.H. and Chan, G.C.F., 2023. Significant healthcare burden and life cost of spinal muscular atrophy: real-world data. *The European Journal of Health Economics*, 24(8), pp.1373–1382. <https://doi.org/10.1007/s10198-022-01548-5>.

Chen, Y.-S., Shih, H.-H., Chen, T.-H., Kuo, C.-H. and Jong, Y.-J., 2012. Prevalence and Risk Factors for Feeding and Swallowing Difficulties in Spinal Muscular Atrophy Types II and III. *The Journal of Pediatrics*, 160(3), pp.447-451.e1. <https://doi.org/10.1016/j.jpeds.2011.08.016>.

Chiriboga, C.A., Swoboda, K.J., Darras, B.T., Iannaccone, S.T., Montes, J., De Vivo, D.C., Norris, D.A., Bennett, C.F. and Bishop, K.M., 2016. Results from a phase 1 study of nusinersen (ISIS-SMN_{Rx}) in children with spinal muscular atrophy. *Neurology*, 86(10), pp.890–897.
<https://doi.org/10.1212/WNL.0000000000002445>.

Ch'ng, G.S., Koh, K., Ahmad-Annuar, A., Taib, F., Koh, C.L. and Lim, E.S.C., 2022. A mixed method study on the impact of living with spinal muscular atrophy in Malaysia from patients' and caregivers' perspectives. *Orphanet Journal of Rare Diseases*, 17(1), p.200. <https://doi.org/10.1186/s13023-022-02351-4>.

Chung, B.H.Y., Wong, V.C.N. and Ip, P., 2004. Spinal Muscular Atrophy: Survival Pattern and Functional Status. *Pediatrics*, 114(5), pp.e548–e553.
<https://doi.org/10.1542/peds.2004-0668>.

Coratti, G., Ricci, M., Capasso, A., D'amico, A., Sansone, V., Bruno, C., Messina, S., Ricci, F., Mongini, T., Coccia, M., Siciliano, G., Pegoraro, E., Turri, M., Filosto, M., Comi, G., Masson, R., Maggi, L., Bruno, I., D'Angelo, M.G., Trabacca, A., Vacchiano, V., Donati, M., Simone, I., Ruggiero, L., Varone, A., Verriello, L., Berardinelli, A., Agosto, C., Pini, A., Maioli, M.A., Passamano, L., Brighina, F., Carboni, N., Garibaldi, M., Zuccarino, R., Gagliardi, D., Siliquini, S., Previtali, S., Taruscio, D., Boccia, S., Pera,

- M.C., Pane, M. and Mercuri, E., 2023. Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies. *Neurology*, 100(11), pp.522–528. <https://doi.org/10.1212/WNL.0000000000201654>.
- D’Amico, A., Mercuri, E., Tiziano, F.D. and Bertini, E., 2011. Spinal muscular atrophy. *Orphanet Journal of Rare Diseases*, 6(1), p.71. <https://doi.org/10.1186/1750-1172-6-71>.
- Darras, B.T., Masson, R., Mazurkiewicz-Beldzińska, M., Rose, K., Xiong, H., Zanolati, E., Baranello, G., Bruno, C., Vlodavets, D., Wang, Y., El-Khairi, M., Gerber, M., Gorni, K., Khwaja, O., Kletzl, H., Scalco, R.S., Fontoura, P. and Servais, L., 2021. Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls. *New England Journal of Medicine*, 385(5), pp.427–435. <https://doi.org/10.1056/NEJMoa2102047>.
- Day, J.W., Finkel, R.S., Chiriboga, C.A., Connolly, A.M., Crawford, T.O., Darras, B.T., Iannaccone, S.T., Kuntz, N.L., Peña, L.D.M., Shieh, P.B., Smith, E.C., Kwon, J.M., Zaidman, C.M., Schultz, M., Feltner, D.E., Tauscher-Wisniewski, S., Ouyang, H., Chand, D.H., Sproule, D.M., Macek, T.A. and Mendell, J.R., 2021. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STRIVE): an open-label, single-arm, multicentre, phase 3 trial. *The Lancet Neurology*, 20(4), pp.284–293. [https://doi.org/10.1016/S1474-4422\(21\)00001-6](https://doi.org/10.1016/S1474-4422(21)00001-6).
- Fauroux, B., Griffon, L., Amaddeo, A., Stremler, N., Mazenq, J., Khirani, S. and Baravalle-Einaudi, M., 2020. Respiratory management of children with spinal muscular atrophy (SMA). *Archives de Pédiatrie*, 27(7), pp.7S29–7S34. [https://doi.org/10.1016/S0929-693X\(20\)30274-8](https://doi.org/10.1016/S0929-693X(20)30274-8).
- Ferrans, C.E., Zerwic, J.J., Wilbur, J.E. and Larson, J.L., 2005. Conceptual Model of Health-Related Quality of Life. *Journal of Nursing Scholarship*, 37(4), pp.336–342. <https://doi.org/10.1111/j.1547-5069.2005.00058.x>.
- Ferro, M.A., Avery, L., Fayed, N., Streiner, D.L., Cunningham, C.E., Boyle, M.H., Lach, L., Glidden, G., Rosenbaum, P.L. and Ronen, G.M., 2017. Child- and parent-reported quality of life trajectories in children with epilepsy: A prospective cohort study. *Epilepsia*, 58(7), pp.1277–1286. <https://doi.org/10.1111/epi.13774>.
- Finkel, R.S., McDermott, M.P., Kaufmann, P., Darras, B.T., Chung, W.K., Sproule, D.M., Kang, P.B., Foley, A.R., Yang, M.L., Martens, W.B., Oskoui, M., Glanzman, A.M., Flickinger, J., Montes, J., Dunaway, S., O’Hagen, J., Quigley, J., Riley, S., Benton, M., Ryan, P.A., Montgomery, M., Marra, J., Gooch, C. and De Vivo, D.C., 2014. Observational study of spinal muscular

atrophy type I and implications for clinical trials. *Neurology*, 83(9), pp.810–817. <https://doi.org/10.1212/WNL.0000000000000741>.

Finkel, R.S., Mercuri, E., Darras, B.T., Connolly, A.M., Kuntz, N.L., Kirschner, J., Chiriboga, C.A., Saito, K., Servais, L., Tizzano, E., Topaloglu, H., Tulinius, M., Montes, J., Glanzman, A.M., Bishop, K., Zhong, Z.J., Gheuens, S., Bennett, C.F., Schneider, E., Farwell, W. and De Vivo, D.C., 2017. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. *New England Journal of Medicine*, 377(18), pp.1723–1732. <https://doi.org/10.1056/NEJMoa1702752>.

Food and Drug Administration, 2019. *FDA approves innovative gene therapy to treat pediatric patients with spinal muscular atrophy, a rare disease and leading genetic cause of infant mortality 2019*.

Fujak, A. and Haaker, G., 2013. Proximal spinal muscular atrophy: current orthopedic perspective. *The Application of Clinical Genetics*, p.113. <https://doi.org/10.2147/TACG.S53615>.

Garratt, A.M., Hansen, T.M., Augestad, L.A., Rand, K. and Stavem, K., 2022. Norwegian population norms for the EQ-5D-5L: results from a general population survey. *Quality of Life Research*, 31(2), pp.517–526. <https://doi.org/10.1007/s11136-021-02938-7>.

Iannaccone, S.T., 2003. Reliability of 4 Outcome Measures in Pediatric Spinal Muscular Atrophy. *Archives of Neurology*, 60(8), p.1130. <https://doi.org/10.1001/archneur.60.8.1130>.

Iannaccone, S.T., Hynan, L.S., Morton, A., Buchanan, R., Limbers, C.A. and Varni, J.W., 2009. The PedsQL[™] in pediatric patients with Spinal Muscular Atrophy: Feasibility, reliability, and validity of the Pediatric Quality of Life Inventory[™] Generic Core Scales and Neuromuscular Module. *Neuromuscular Disorders*, 19(12), pp.805–812. <https://doi.org/10.1016/j.nmd.2009.09.009>.

Kaufmann, P., McDermott, M.P., Darras, B.T., Finkel, R.S., Sproule, D.M., Kang, P.B., Oskoui, M., Constantinescu, A., Gooch, C.L., Foley, A.R., Yang, M.L., Tawil, R., Chung, W.K., Martens, W.B., Montes, J., Battista, V., O'Hagen, J., Dunaway, S., Flickinger, J., Quigley, J., Riley, S., Glanzman, A.M., Benton, M., Ryan, P.A., Punyanitya, M., Montgomery, M.J., Marra, J., Koo, B. and De Vivo, D.C., 2012. Prospective cohort study of spinal muscular atrophy types 2 and 3. *Neurology*, 79(18), pp.1889–1897. <https://doi.org/10.1212/WNL.0b013e318271f7e4>.

- Keinath, M.C., Prior, D.E. and Prior, T.W., 2021. Spinal Muscular Atrophy: Mutations, Testing, and Clinical Relevance. *The Application of Clinical Genetics*, Volume 14, pp.11–25. <https://doi.org/10.2147/TACG.S239603>.
- Kinnear, W., Dring, K., Kinnear, K., Hansel, J. and Sovani, M., 2021. How to eat, drink and speak on non-invasive ventilation. *Chronic Respiratory Disease*, 18. <https://doi.org/10.1177/14799731211061156>.
- Kissel, J.T., Scott, C.B., Reyna, S.P., Crawford, T.O., Simard, L.R., Krosschell, K.J., Acsadi, G., Elsheik, B., Schroth, M.K., D’Anjou, G., LaSalle, B., Prior, T.W., Sorenson, S., Maczulski, J.A., Bromberg, M.B., Chan, G.M. and Swoboda, K.J., 2011. SMA CARNI-VAL TRIAL PART II: A Prospective, Single-Armed Trial of L-Carnitine and Valproic Acid in Ambulatory Children with Spinal Muscular Atrophy. *PLoS ONE*, 6(7), p.e21296. <https://doi.org/10.1371/journal.pone.0021296>.
- Klug, C., Schreiber-Katz, O., Thiele, S., Schorling, E., Zowe, J., Reilich, P., Walter, M.C. and Nagels, K.H., 2016. Disease burden of spinal muscular atrophy in Germany. *Orphanet Journal of Rare Diseases*, 11(1), p.58. <https://doi.org/10.1186/s13023-016-0424-0>.
- Kocova, H., Dvorackova, O., Vondracek, P. and Haberlova, J., 2014. Health-Related Quality of Life in Children and Adolescents With Spinal Muscular Atrophy in the Czech Republic. *Pediatric Neurology*, 50(6), pp.591–594. <https://doi.org/10.1016/j.pediatrneurol.2014.01.037>.
- Kolb, S.J. and Kissel, J.T., 2015. Spinal Muscular Atrophy. *Neurologic Clinics*, 33(4), pp.831–846. <https://doi.org/10.1016/j.ncl.2015.07.004>.
- Landfeldt, E., Leibrock, B., Hussong, J., Thiele, S., Abner, S., Walter, M.C., Moehler, E., Zemlin, M., Dillmann, U. and Flotats-Bastardas, M., 2024. Self-Reported Health-Related Quality of Life of Children with Spinal Muscular Atrophy: Preliminary Insights from a Nationwide Patient Registry in Germany. *Journal of Neuromuscular Diseases*, 11(1), pp.117–128. <https://doi.org/10.3233/JND-230071>.
- Landfeldt, E., Pechmann, A., McMillan, H.J., Lochmüller, H. and Sejersen, T., 2021. Costs of Illness of Spinal Muscular Atrophy: A Systematic Review. *Applied Health Economics and Health Policy*, 19(4), pp.501–520. <https://doi.org/10.1007/s40258-020-00624-2>.
- Landfeldt, E., Udo, C., Lövgren, M., Sejersen, T. and Kreicbergs, U., 2023. Health-related quality of life of children with spinal muscular atrophy in Sweden: A prospective cohort study in the era of disease-modifying therapy. *European Journal of Paediatric Neurology*, 46, pp.67–73. <https://doi.org/10.1016/j.ejpn.2023.06.008>.

- Lin, X.-J., Lin, I.-M. and Fan, S.-Y., 2013. Methodological issues in measuring health-related quality of life. *Tzu Chi Medical Journal*, 25(1), pp.8–12. <https://doi.org/10.1016/j.tcmj.2012.09.002>.
- McMillan, H.J., Gerber, B., Cowling, T., Khuu, W., Mayer, M., Wu, J.W., Maturi, B., Klein-Panneton, K., Cabalteja, C. and Lochmüller, H., 2021. Burden of Spinal Muscular Atrophy (SMA) on Patients and Caregivers in Canada. *Journal of Neuromuscular Diseases*, 8(4), pp.553–568. <https://doi.org/10.3233/JND-200610>.
- McMillan, H.J., Proud, C.M., Farrar, M.A., Alexander, I.E., Muntoni, F. and Servais, L., 2022. Onasemnogene abeparvovec for the treatment of spinal muscular atrophy. *Expert Opinion on Biological Therapy*, 22(9), pp.1075–1090. <https://doi.org/10.1080/14712598.2022.2066471>.
- Megari, K., 2013. Quality of life in chronic disease patients. *Health Psychology Research*, [online] 1(3), p.27. <https://doi.org/10.4081/hpr.2013.e27>.
- Mercuri, E., Darras, B.T., Chiriboga, C.A., Day, J.W., Campbell, C., Connolly, A.M., Iannaccone, S.T., Kirschner, J., Kuntz, N.L., Saito, K., Shieh, P.B., Tulinius, M., Mazzone, E.S., Montes, J., Bishop, K.M., Yang, Q., Foster, R., Gheuens, S., Bennett, C.F., Farwell, W., Schneider, E., De Vivo, D.C. and Finkel, R.S., 2018a. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. *New England Journal of Medicine*, 378(7), pp.625–635. <https://doi.org/10.1056/NEJMoa1710504>.
- Mercuri, E., Finkel, R.S., Muntoni, F., Wirth, B., Montes, J., Main, M., Mazzone, E.S., Vitale, M., Snyder, B., Quijano-Roy, S., Bertini, E., Davis, R.H., Meyer, O.H., Simonds, A.K., Schroth, M.K., Graham, R.J., Kirschner, J., Iannaccone, S.T., Crawford, T.O., Woods, S., Qian, Y., Sejersen, T., Muntoni, F., Wirth, B., Tiziano, F.D., Kirschner, J., Tizzano, E., Topaloglu, H., Swoboda, K., Laing, N., Kayoko, S., Prior, T., Chung, W.K., Wu, S.-M., Montes, J., Mazzone, E., Main, M., Coleman, C., Gee, R., Glanzman, A., Kroksmark, A.-K., Krosschell, K., Nelson, L., Rose, K., Stępień, A., Vuillerot, C., Vitale, M., Snyder, B., Quijano-Roy, S., Dubousset, J., Farrington, D., Flynn, J., Halanski, M., Hasler, C., Miladi, L., Reilly, C., Roye, B., Sponseller, P., Yazici, M., Hurst, R., Bertini, E., Tarrant, S., Barja, S., Bertoli, S., Crawford, T., Foust, K., Kyle, B., Rodan, L., Roper, H., Seffrood, E., Swoboda, K. and Szlagatys-Sidorkiewicz, A., 2018b. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. *Neuromuscular Disorders*, 28(2), pp.103–115. <https://doi.org/10.1016/j.nmd.2017.11.005>.
- Nguyen, T.M., 2022. *Health-Related Quality of Life in Children with Spinal Muscular Atrophy*. [online] The University of Western Ontario. Available at: <<https://ir.lib.uwo.ca/etd/8802>> [Accessed 28 November 2023].

- Nishio, H., Niba, E.T.E., Saito, T., Okamoto, K., Takeshima, Y. and Awano, H., 2023. Spinal Muscular Atrophy: The Past, Present, and Future of Diagnosis and Treatment. *International Journal of Molecular Sciences*, 24(15), p.11939. <https://doi.org/10.3390/ijms241511939>.
- Nurputra, D.K., Lai, P.S., Harahap, N.I.F., Morikawa, S., Yamamoto, T., Nishimura, N., Kubo, Y., Takeuchi, A., Saito, T., Takeshima, Y., Tohyama, Y., Tay, S.K., Low, P.S., Saito, K. and Nishio, H., 2013. Spinal Muscular Atrophy: From Gene Discovery to Clinical Trials. *Annals of Human Genetics*, 77(5), pp.435–463. <https://doi.org/10.1111/ahg.12031>.
- Oprea, G.E., Kröber, S., McWhorter, M.L., Rossoll, W., Müller, S., Krawczak, M., Bassell, G.J., Beattie, C.E. and Wirth, B., 2008. Plastin 3 Is a Protective Modifier of Autosomal Recessive Spinal Muscular Atrophy. *Science*, 320(5875), pp.524–527. <https://doi.org/10.1126/science.1155085>.
- Oskoui, M., Levy, G., Garland, C.J., Gray, J.M., O'Hagen, J., De Vivo, D.C. and Kaufmann, P., 2007. The changing natural history of spinal muscular atrophy type 1. *Neurology*, 69(20), pp.1931–1936. <https://doi.org/10.1212/01.wnl.0000290830.40544.b9>.
- Peña-Longobardo, L.M., Aranda-Reneo, I., Oliva-Moreno, J., Litzkendorf, S., Durand-Zaleski, I., Tizzano, E. and López-Bastida, J., 2020. The Economic Impact and Health-Related Quality of Life of Spinal Muscular Atrophy. An Analysis across Europe. *International Journal of Environmental Research and Public Health*, 17(16), p.5640. <https://doi.org/10.3390/ijerph17165640>.
- Prior, T.W., Leach, M.E., Finanger, E., Adam, M.P., Feldman, J. and Mirzaa, G.M., 2000. *Spinal Muscular Atrophy*.
- Prior, T.W., Snyder, P.J., Rink, B.D., Pearl, D.K., Pyatt, R.E., Mihal, D.C., Conlan, T., Schmalz, B., Montgomery, L., Ziegler, K., Noonan, C., Hashimoto, S. and Garner, S., 2010. Newborn and carrier screening for spinal muscular atrophy. *American Journal of Medical Genetics Part A*, 152A(7), pp.1608–1616. <https://doi.org/10.1002/ajmg.a.33474>.
- Puka, K., Ferro, M.A., Camfield, C.S., Levin, S.D., Smith, M. Lou, Wiebe, S., Zou, G., Anderson, K.K. and Speechley, K.N., 2020. Trajectories of quality of life 10 years following a diagnosis of epilepsy in childhood. *Epilepsia*, 61(7), pp.1453–1463. <https://doi.org/10.1111/epi.16579>.
- Ropars, J., Peudenier, S., Genot, A., Barnerias, C. and Espil, C., 2020. Multidisciplinary approach and psychosocial management of spinal muscular atrophy (SMA). *Archives de Pédiatrie*, 27(7), pp.7S45-7S49. [https://doi.org/10.1016/S0929-693X\(20\)30277-3](https://doi.org/10.1016/S0929-693X(20)30277-3).

- Santos, L.S., Silva, V.L., Neves, V.A., Ribeiro, E.S., Silva, M.H.M. de L. and Gama, G.L., 2022. Spinal muscular atrophy: health related quality of life and burden to parents. *REVISTA CIÊNCIAS EM SAÚDE*, 12(4), pp.35–41. <https://doi.org/10.21876/rscsci.v12i4.1340>.
- Sintusek, P., Catapano, F., Angkathunkayul, N., Marrosu, E., Parson, S.H., Morgan, J.E., Muntoni, F. and Zhou, H., 2016. Histopathological Defects in Intestine in Severe Spinal Muscular Atrophy Mice Are Improved by Systemic Antisense Oligonucleotide Treatment. *PLOS ONE*, 11(5), p.e0155032. <https://doi.org/10.1371/journal.pone.0155032>.
- Strauss, K., Muntoni, F., Farrar, M., Saito, K., Mendell, J., Servais, L., McMillan, H., Swoboda, K., Kwon, J., Zaidman, C., Chiriboga, C., Iannaccone, S., Krueger, J., Parsons, J., Shieh, P., Kavanagh, S., Chand, D., Tauscher-Wisniewski, S. and Macek, T., 2021. Onasemnogene Apeparvovec Gene Therapy in Presymptomatic Spinal Muscular Atrophy (SMA): SPR1NT Study Update in Children with 2 Copies of SMN2 (4190). *Neurology*, 96(15_supplement). https://doi.org/10.1212/WNL.96.15_supplement.4190.
- Sun, J., Harrington, M.A. and Porter, B., 2023a. Sex Difference in Spinal Muscular Atrophy Patients – are Males More Vulnerable? *Journal of Neuromuscular Diseases*, 10(5), pp.847–867. <https://doi.org/10.3233/JND-230011>.
- Sun, J., Harrington, M.A. and Porter, B., 2023b. Sex Difference in Spinal Muscular Atrophy Patients – are Males More Vulnerable? *Journal of Neuromuscular Diseases*, 10(5), pp.847–867. <https://doi.org/10.3233/JND-230011>.
- Swoboda, K.J., Scott, C.B., Crawford, T.O., Simard, L.R., Reyna, S.P., Krossschell, K.J., Acsadi, G., Elsheim, B., Schroth, M.K., D’Anjou, G., LaSalle, B., Prior, T.W., Sorenson, S.L., Maczulski, J.A., Bromberg, M.B., Chan, G.M. and Kissel, J.T., 2010. SMA CARNI-VAL Trial Part I: Double-Blind, Randomized, Placebo-Controlled Trial of L-Carnitine and Valproic Acid in Spinal Muscular Atrophy. *PLoS ONE*, [online] 5(8), p.e12140. <https://doi.org/10.1371/journal.pone.0012140>.
- Vega, P., Glisser, C., Castiglioni, C., Amézquita, M.V., Quirola, M. and Barja Yañez, S., 2020a. Calidad de vida en niños y adolescentes con Atrofia Muscular Espinal. *Revista Chilena de Pediatría*, 91(4). <https://doi.org/10.32641/rchped.v91i4.1443>.
- Vega, P., Glisser, C., Castiglioni, C., Amézquita, M.V., Quirola, M. and Barja Yañez, S., 2020b. Calidad de vida en niños y adolescentes con Atrofia Muscular Espinal. *Revista Chilena de Pediatría*, 91(4). <https://doi.org/10.32641/rchped.v91i4.1443>.

- Verhaart, I.E.C., Robertson, A., Wilson, I.J., Aartsma-Rus, A., Cameron, S., Jones, C.C., Cook, S.F. and Lochmüller, H., 2017. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy – a literature review. *Orphanet Journal of Rare Diseases*, 12(1), p.124. <https://doi.org/10.1186/s13023-017-0671-8>.
- De Vivo, D.C., Bertini, E., Swoboda, K.J., Hwu, W.-L., Crawford, T.O., Finkel, R.S., Kirschner, J., Kuntz, N.L., Parsons, J.A., Ryan, M.M., Butterfield, R.J., Topaloglu, H., Ben-Omran, T., Sansone, V.A., Jong, Y.-J., Shu, F., Staropoli, J.F., Kerr, D., Sandrock, A.W., Stebbins, C., Petrillo, M., Braley, G., Johnson, K., Foster, R., Gheuens, S., Bhan, I., Reyna, S.P., Fradette, S. and Farwell, W., 2019. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. *Neuromuscular Disorders*, 29(11), pp.842–856. <https://doi.org/10.1016/j.nmd.2019.09.007>.
- Van Wilder, L., Pype, P., Mertens, F., Rammant, E., Clays, E., Devleeschauwer, B., Boeckxstaens, P. and De Smedt, D., 2021. Living with a chronic disease: insights from patients with a low socioeconomic status. *BMC Family Practice*, 22(1), p.233. <https://doi.org/10.1186/s12875-021-01578-7>.
- Wiwaha, G., Sari, D.M., Biben, V., Sunjaya, D.K. and Hilmanto, D., 2022a. Translation and validation of Indonesian version of Pediatric Quality of Life InventoryTM (PedsQLTM) Neuromuscular Module. *Health and Quality of Life Outcomes*, 20(1), p.33. <https://doi.org/10.1186/s12955-022-01933-x>.
- Wiwaha, G., Sari, D.M., Biben, V., Sunjaya, D.K. and Hilmanto, D., 2022b. Translation and validation of Indonesian version of Pediatric Quality of Life InventoryTM (PedsQLTM) Neuromuscular Module. *Health and Quality of Life Outcomes*, 20(1), p.33. <https://doi.org/10.1186/s12955-022-01933-x>.
- Wohnrade, C., Velling, A.-K., Mix, L., Wurster, C.D., Cordts, I., Stolte, B., Zeller, D., Uzelac, Z., Platen, S., Hagenacker, T., Deschauer, M., Lingor, P., Ludolph, A.C., Lulé, D., Petri, S., Osmanovic, A. and Schreiber-Katz, O., 2023a. Health-Related Quality of Life in Spinal Muscular Atrophy Patients and Their Caregivers—A Prospective, Cross-Sectional, Multi-Center Analysis. *Brain Sciences*, 13(1), p.110. <https://doi.org/10.3390/brainsci13010110>.
- Wohnrade, C., Velling, A.-K., Mix, L., Wurster, C.D., Cordts, I., Stolte, B., Zeller, D., Uzelac, Z., Platen, S., Hagenacker, T., Deschauer, M., Lingor, P., Ludolph, A.C., Lulé, D., Petri, S., Osmanovic, A. and Schreiber-Katz, O., 2023b. Health-Related Quality of Life in Spinal Muscular Atrophy Patients and Their Caregivers—A Prospective, Cross-Sectional, Multi-Center Analysis. *Brain Sciences*, 13(1), p.110. <https://doi.org/10.3390/brainsci13010110>.

- Wurster, C.D. and Ludolph, A.C., 2018. Nusinersen for spinal muscular atrophy. *Therapeutic Advances in Neurological Disorders*, 11. <https://doi.org/10.1177/1756285618754459>.
- Yang, F., Devlin, N. and Luo, N., 2019. Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter? *Value in Health*, 22(1), pp.45–49. <https://doi.org/10.1016/j.jval.2018.05.008>.
- Yao, M., Ma, Y., Qian, R., Xia, Y., Yuan, C., Bai, G. and Mao, S., 2021a. Quality of life of children with spinal muscular atrophy and their caregivers from the perspective of caregivers: a Chinese cross-sectional study. *Orphanet Journal of Rare Diseases*, 16(1), p.7. <https://doi.org/10.1186/s13023-020-01638-8>.
- Yao, M., Ma, Y., Qian, R., Xia, Y., Yuan, C., Bai, G. and Mao, S., 2021b. Quality of life of children with spinal muscular atrophy and their caregivers from the perspective of caregivers: a Chinese cross-sectional study. *Orphanet Journal of Rare Diseases*, 16(1), p.7. <https://doi.org/10.1186/s13023-020-01638-8>.
- Zamani, G., Ashrafi, M.R., Ghabeli, H., Akbari, M.G., Mohammadi, M., Badv, R.S., Hosseinpour, S., Haghighi, R., Pourbakhtyaran, E., Khosroshahi, N. and Heidari, M., 2022. The quality of life in children with spinal muscular atrophy: a case–control study. *BMC Pediatrics*, 22(1), p.708. <https://doi.org/10.1186/s12887-022-03751-y>.
- Zappa, G., LoMauro, A., Baranello, G., Cavallo, E., Corti, P., Mastella, C. and Costantino, M.A., 2021. Intellectual abilities, language comprehension, speech, and motor function in children with spinal muscular atrophy type 1. *Journal of Neurodevelopmental Disorders*, 13(1), p.9. <https://doi.org/10.1186/s11689-021-09355-4>.